Growth & profitability
- Revenue has grown 56.6% per year over the past 5 years.
- Operating margin has expanded, at 11.9% in the latest year.
Financial health
- Operating income covered interest expense 1.1× in the latest year.
ARWR Financials Arrowhead Pharmaceuticals, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $829M | -$2M | 0.0% | 11.9% | $157M | — | $227M |
| 2024 | $4M | -$599M | 0.0% | -16927.1% | -$604M | — | $103M |
| 2023 | $241M | -$205M | 0.0% | -85.2% | -$331M | — | $111M |
| 2022 | $243M | -$176M | 0.0% | -73.4% | -$189M | — | $108M |
| 2021 | $138M | -$141M | 0.0% | -107.8% | $148M | — | $184M |
| 2020 | $88M | -$85M | 0.0% | -105.9% | -$108M | — | $144M |
| 2019 | $169M | $68M | 0.0% | 36.3% | $161M | — | $222M |
| 2018 | $16M | -$54M | 0.0% | -346.5% | -$49M | — | $30M |
| 2017 | $31M | -$34M | 0.0% | -117.8% | -$32M | — | $25M |
| 2016 | — | -$82M | — | — | -$68M | — | — |
| 2015 | — | -$92M | — | — | — | — | — |
| 2014 | — | -$59M | — | — | — | — | — |
| 2014 | — | -$191M | — | — | — | — | — |
| 2013 | — | -$177M | — | — | — | — | — |
| 2013 | — | -$31M | — | — | — | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $74M | -$133M | 0.0% | -191.6% | $82M | — | $189M |
| Dec '25 | $264M | $31M | 0.0% | 15.5% | $11M | — | $202M |
| Sep '25 | $256M | -$24M | 0.0% | 17.2% | $13M | — | $227M |
| Jun '25 | $28M | -$175M | 0.0% | -596.2% | -$157M | — | $130M |
| Mar '25 | $543M | $370M | 0.0% | 70.2% | $455M | — | $186M |
| Dec '24 | $3M | -$173M | 0.0% | -6456.5% | -$154M | — | $54M |
| Sep '24 | $0 | -$171M | — | — | -$162M | — | $103M |
| Jun '24 | $0 | -$171M | — | — | -$130M | — | $69M |
| Mar '24 | $0 | -$125M | — | — | -$126M | — | $128M |
| Dec '23 | $4M | -$133M | 0.0% | -3845.3% | -$186M | — | $58M |
| Sep '23 | $16M | -$110M | 0.0% | -673.0% | -$90M | — | $111M |
| Jun '23 | $16M | -$103M | 0.0% | -649.0% | -$67M | — | $105M |
| Mar '23 | $146M | $49M | 0.0% | 32.9% | -$59M | — | $135M |
| Dec '22 | $63M | -$41M | 0.0% | -67.4% | -$114M | — | $202M |
| Sep '22 | $32M | -$86M | 0.0% | -265.5% | -$101M | — | $108M |
| Jun '22 | $32M | -$72M | 0.0% | -224.9% | -$78M | — | — |
| Mar '22 | $152M | $44M | 0.0% | 27.4% | $58M | — | — |
| Dec '21 | $27M | -$63M | 0.0% | -230.8% | -$67M | — | — |
| Sep '21 | $38M | -$63M | 0.0% | -169.5% | -$32M | — | $184M |
| Jun '21 | $46M | -$30M | 0.0% | -69.4% | -$34M | — | — |
Valuation over time
How the market has priced ARWR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 14.7× (Mar '23) to 13.5× (Jun '26).
P/S
Frequently asked questions
Is ARWR growing its revenue and profit?
Over the past 5 years, Arrowhead Pharmaceuticals, Inc.'s revenue has grown 56.6% per year. These are computed facts, not advice.
How much debt does ARWR have?
As of FY2025, Arrowhead Pharmaceuticals, Inc. reported — of total debt against $227M of cash; operating income covered interest expense 1.1×.
What is ARWR's profit margin?
In FY2025, gross margin was —, operating margin 11.9%, and net margin -0.2%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.